Ondexxya (Andexanet Alfa)

Andexanet alfa, the active ingredient in Ondexxya, is a recombinant factor Xa decoy protein presented as a solution for injection for intravenous use. It reverses anticoagulation caused by factor Xa inhibitors such as apixaban and rivaroxaban in patients who require rapid restoration of normal clotting.

GNH USA supplies Ondexxya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide globally. The product meets EU regulatory standards and is distributed under strict quality controls.

Ondexxya is used to reverse the anticoagulant effects of factor Xa inhibitors in clinical settings.

- Apixaban reversal: restores normal coagulation in patients receiving apixaban who need urgent surgery or experience major bleeding. - Rivaroxaban reversal: restores normal coagulation in patients receiving rivaroxaban who need urgent surgery or experience major bleeding. - Emergency bleeding management: provides rapid reversal of anticoagulation to control life‑threatening hemorrhage.

The safety profile of Ondexxya includes a range of observed adverse reactions.

Common Side Effects: - Infusion‑related reactions: mild flushing, warmth, or erythema at the injection site. - Hypotension: transient drops in blood pressure during or shortly after infusion. - Fever: low‑grade temperature elevation. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Thrombotic events: arterial or venous thrombosis such as stroke, myocardial infarction, or deep‑vein thrombosis. - Anaphylaxis: severe allergic reaction with airway compromise. - Cardiac arrest: sudden loss of cardiac function. - Disseminated intravascular coagulation: abnormal clotting throughout the circulation. - Severe recurrent bleeding: paradoxical worsening of hemorrhage after reversal.

Before using Ondexxya, clinicians should consider several precautionary measures to minimize risk.

- Renal impairment: evaluate thrombotic risk and monitor renal function closely. - Hepatic impairment: assess bleeding risk and adjust monitoring as needed. - History of thrombosis: weigh benefit‑risk ratio due to potential for clot formation. - Concurrent pro‑coagulant therapy: use with caution as additive thrombosis risk may increase. - Pregnancy and lactation: limited clinical data; prescribe only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondexxya may interact with other medicines that affect coagulation or hemostasis.

Major Interactions (Avoid): - Concurrent use of pro‑coagulant agents (e.g., factor concentrates): may increase risk of thrombosis. - Simultaneous administration of other anticoagulant reversal agents: can cause unpredictable coagulation changes. - Known hypersensitivity to andexanet alfa or any excipients: contraindicated.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., aspirin, clopidogrel): may alter bleeding control and require monitoring. - Strong enzyme inducers: may affect clearance of co‑administered drugs, though impact on andexanet alfa is minimal. - Ongoing factor Xa inhibitor therapy: timing of reversal and re‑initiation should be carefully managed.